Hektoen HH, Tsuruda KM, Brustugun OT, Neumann K, Andreassen BK(2025) Real-world comparison of pembrolizumab alone and combined with chemotherapy in metastatic lung adenocarcinoma patients with PD-L1 expression ≥50 ESMO Open, 10(5), 105073(in press) DOI 10.1016/j.esmoop.2025.105073, PubMed 40305908
Tsuruda KM, Hektoen HH, Aamelfot C, Andreassen BK(2025) Let's talk about sex: Survival among females and males in a real-world cohort treated with pembrolizumab for non-small cell lung cancer Int J Cancer(in press) DOI 10.1002/ijc.35445, PubMed 40298324
Schytte T, Knap MM, Kristiansen C, Appelt AL, Khalil A, Peucelle C, Lutz CM, Møller DS, Sande EPS, Sundby F, Persson G, Schmidt H, Land LH, Rogg L, Pøhl M, Lund MD, Nielsen M, Levin N, Hansen O, Thing RS, Borissova S, Halvorsen T, Nielsen TB, Hansen TS, Haakensen VDet al.(2025) Toxicity Within 6 Months of Heterogeneous Fluorodeoxyglucose-Guided Radiotherapy Dose Escalation for Locally Advanced Non-Small Cell Lung Cancer in the Scandinavian Randomized Phase III NARLAL2 Trial J Clin Oncol, JCO2401386(in press) DOI 10.1200/JCO-24-01386, PubMed 40249893
